(NASDAQ: IOVA) Iovance Biotherapeutics's forecast annual revenue growth rate of 34.88% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.37%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.15%.
Iovance Biotherapeutics's revenue in 2026 is $285,608,000.On average, 13 Wall Street analysts forecast IOVA's revenue for 2026 to be $164,741,524,028, with the lowest IOVA revenue forecast at $154,025,466,524, and the highest IOVA revenue forecast at $173,372,415,343. On average, 12 Wall Street analysts forecast IOVA's revenue for 2027 to be $228,439,555,842, with the lowest IOVA revenue forecast at $196,907,556,636, and the highest IOVA revenue forecast at $265,825,201,459.
In 2028, IOVA is forecast to generate $317,999,006,431 in revenue, with the lowest revenue forecast at $245,040,514,925 and the highest revenue forecast at $426,633,039,378.